Consider what happened in Walker County, Georgia, in the fall of 2025. Multiple middle schoolers became ill after eating gummies at school, though even the eventual headcount was never fully settled, with local reports ranging from three to five students. Emergency room physicians diagnosed a kratom overdose based on the clinical picture, and within hours the story was national: Kratom gummies had hospitalized children. Investigators collected one of the gummies and sent it to a university laboratory. The result, reported weeks later, was that the gummy contained no kratom, and none of the 64 other drugs the laboratory screened for. The sheriff closed the case and acknowledged that the true cause of the children’s illness was never identified.

Notice the sequence. A clinical impression became a diagnosis, the diagnosis became a headline, and the headline became another entry in the case against “kratom,” all before a single laboratory result existed. When the result finally arrived, it supported none of it. Yet the original headlines are still online, uncorrected, and the laboratory finding that cleared the product reached a small fraction of the audience the first story did. This is not an argument that kratom is harmless. It is a reminder that the label now arrives faster than the evidence, and that the gap between the two is where bad policy is made.

What is kratom and why does it matter?

In a municipal meeting this year, I watched an official sum up the problem in a single sentence. “We cannot tell the difference, so let’s just ban all of it.” He was talking about kratom. He was sincere, he was trying to protect his community, and he was about to make a decision built on a nomenclature error. That error is now shaping public health policy across the country, creating mass hysteria and misinformation. The truth is that there are many quality kratom manufacturers using good manufacturing practices (GMP) and testing each batch of kratom through a third-party qualified lab which produces a certificate of analysis to ensure the natural profile of the alkaloids, no adulterants or contaminants. States with a Kratom Consumer Protection Act (KCPA) require vendors to demonstrate these alkaloid levels, label products according to Food and Drug Administration (FDA) standards, and use GMP to prepare products. Clinicians are among the few people positioned to correct the misinformation and, importantly, understand the difference between the safety of the natural botanical and synthetic substances.

Here is the confusion. The word “kratom” is being used to describe things that are not pharmacologically the same. Kratom is a traditional leaf of Mitragyna speciosa, taken as a powder or a tea, used for generations in Southeast Asia. Its dominant alkaloid is mitragynine, a partial mu-opioid agonist with a ceiling on its effects and a long record of human use. A key distinction is the whole leaf does not lead to opioid-like respiratory depression. An FDA single ascending dose study did not demonstrate respiratory depression even at 12 grams (24 capsules) in 5 minutes, which was the highest level tested. This study adds to a growing body of safety data that includes an open National Institutes of Health study on a purified version of the major alkaloid mitragynine as a potential treatment for opioid use disorder.

7-hydroxymitragynine (7-OH) does occur in trace amounts as a result of oxidation during the drying of the leaf. It also forms in the body as a metabolite of mitragynine. The biological metabolism of some mitragynine to 7-OH occurs slowly through the gut and liver at a fractional rate. This level of naturally occurring 7-OH does not pose harm to humans. Many products now sold in gas stations and smoke shops are not the traditional ground powder from the leaf. They are made by chemically converting mitragynine into 7-OH and concentrating it far beyond anything the plant produces. 7-OH is a substantially more potent mu-opioid agonist than mitragynine, and functional studies have found it roughly 13 times more potent than morphine itself. It is sold as tablets, shots, and gummies, and it is frequently marketed in packaging and flavors that appeal to young people.

So when we say “kratom,” the true meaning describes a leaf with a centuries-long history of use, not a semisynthetic opioid concentrate with no history of use at those doses and no clinical trials to characterize its safety. These are not variations on a theme. They are different exposures with different risks.

The concentrated 7-OH products are what generated the alarm. They are what raised the adverse-event signals, and they are what prompted the marketing-to-minors concerns that reached legislators and city councils. Several other substances that have been falsely marketed as kratom have been placed in Schedule I. The Drug Enforcement Administration (DEA) placed mitragynine pseudoindoxyl (MGPI), MGM-15, and MGM-16 in Schedule I for two years, through August 26, 2028. An announcement is expected soon on the temporary scheduling of concentrated 7-OH. The Department of Health and Human Services, FDA, and DEA have been consistent on this point, and the Department of Justice reinforced it in an August 25, 2026, statement: “This action is directed at deliberately manufactured and concentrated opioid products, not traditional botanical kratom.”

That alarm regarding gas station and vape shop products is not irrational. But the response to it has too often been to reach for the only word everyone recognizes, “kratom,” and ban the leaf along with the synthetics. When we cannot distinguish, we default to erasure. And erasure has a cost. Banning the entire plant sweeps away the traditional leaf, the product with the actual history of use and decades of research, while doing little to address why the concentrated products became popular in the first place. It also pushes people who were managing chronic pain or opioid withdrawal with the leaf toward the illicit market, which is the opposite of what anyone in that council room intended.

Whatever one thinks of scheduling as a tool, the structure of that action is worth noticing. Federal regulators, working from laboratory data, treated the concentrate and the leaf as two different things and wrote the line between them into the rule itself. The distinction, in other words, is not beyond the reach of policy. The open question is whether the county boards and city councils writing local ordinances know that the distinction exists, and that the tools to make it are already on the table. According to the American Kratom Association, twenty-one states have passed a KCPA rather than leaving local jurisdictions to create their own rules.

Tennessee’s kratom ban carries Matthew Davenport’s name. He died in 2024 at a halfway house for alcohol recovery, and the Hamilton County medical examiner attributed his death to diphenhydramine, mitragynine, duloxetine, and buspirone intoxication. The toxicology tells a more complicated story than that single line suggests. His mitragynine level was 810 ng/mL, below the lower bound of the only published reference range for mitragynine in fatality cases, a range built from cases where mitragynine was never found alone. His diphenhydramine level, by contrast, was 3,000 ng/mL: toxic under every published forensic reference range. He was also taking duloxetine and buspirone, a combination that carries an increased risk of serotonin syndrome. The medical examiner’s report did not weigh the relative contribution of each substance and did not identify a mechanism by which mitragynine caused or contributed to death. A statewide ban now carries his name. The forensic record it rests on does not clearly support that attribution.

This is where clinicians come in, and it starts in the exam room. “Do you use kratom?” is no longer a sufficient question. The answer could mean a cup of leaf tea or a high-dose 7-OH tablet, and the clinical implications are not the same. We ask patients which opioid, which benzodiazepine, which formulation. We need that same specificity here. What product. What form. Leaf or concentrate. How much, and how often. The label usually tells the story, because the concentrated products advertise their 7-OH content openly. However, the more we stigmatize and shame patients, the less likely they are to honestly disclose what they are taking.

That specificity matters for more than an accurate chart. It matters because clinicians are trusted voices in exactly the rooms where this conflation does its damage. When a health officer, a school administrator, or a council member says, “We cannot tell the difference,” a clinician who can explain the difference improves the decision. Not toward permissiveness, and not toward panic, but toward precision.

Drug policy routinely allows the most sensational, least representative form of a substance to define the public’s perception of the entire plant. The rare and the extreme crowd out the ordinary and well-characterized. When that happens, we regulate the term instead of the plant, and we lose the distinctions that protect people.

Kratom is a case study in that pattern, unfolding in real time. The leaf and the concentrate falsely share a name and almost nothing else that matters clinically. If we keep treating them as one thing, we will keep making the same error that official made out loud: banning what we did not take the time to distinguish. Clinicians can insist on the distinction. In this debate, that may be the most useful thing we do.

Heidi Sykora is a retired nurse practitioner, former health care executive, and the volunteer chief scientific officer of the International Plant and Herbal Alliance. Her writing and advocacy focus on evidence-based interventions that improve patient outcomes and experiences.

Disclosure: The author is a volunteer chief scientific officer for the International Plant and Herbal Alliance (IPHA), a 501(c)(3) nonprofit focused on science-based public education on botanical products. IPHA reimburses her travel expenses for speaking and educational engagements related to kratom. She has no financial ties to the kratom industry.